694 related articles for article (PubMed ID: 16322018)
1. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
Hippisley-Cox J; Coupland C; Logan R
BMJ; 2005 Dec; 331(7528):1310-6. PubMed ID: 16322018
[TBL] [Abstract][Full Text] [Related]
2. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.
Nørgård B; Pedersen L; Johnsen SP; Tarone RE; McLaughlin JK; Friis S; Sørensen HT
Aliment Pharmacol Ther; 2004 Apr; 19(7):817-25. PubMed ID: 15043523
[TBL] [Abstract][Full Text] [Related]
3. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study.
Rahme E; Nedjar H; Bizzi A; Morin S
Aliment Pharmacol Ther; 2007 Nov; 26(10):1387-98. PubMed ID: 17892525
[TBL] [Abstract][Full Text] [Related]
4. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
Hippisley-Cox J; Coupland C
BMJ; 2005 Jun; 330(7504):1366. PubMed ID: 15947398
[TBL] [Abstract][Full Text] [Related]
5. Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis.
Sørensen HT; Jacobsen J; Nørgaard M; Pedersen L; Johnsen SP; Baron JA
Aliment Pharmacol Ther; 2006 Jul; 24(1):111-6. PubMed ID: 16803609
[TBL] [Abstract][Full Text] [Related]
6. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors.
Thomsen RW; Riis A; Christensen S; McLaughlin JK; Sørensen HT
Aliment Pharmacol Ther; 2006 Nov; 24(10):1431-8. PubMed ID: 17032286
[TBL] [Abstract][Full Text] [Related]
7. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
[TBL] [Abstract][Full Text] [Related]
8. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
Battistella M; Mamdami MM; Juurlink DN; Rabeneck L; Laupacis A
Arch Intern Med; 2005 Jan; 165(2):189-92. PubMed ID: 15668365
[TBL] [Abstract][Full Text] [Related]
9. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
Graham DJ; Campen D; Hui R; Spence M; Cheetham C; Levy G; Shoor S; Ray WA
Lancet; 2005 Feb 5-11; 365(9458):475-81. PubMed ID: 15705456
[TBL] [Abstract][Full Text] [Related]
10. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
Chan FK; Graham DY
Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease.
Höer A; Gothe H; Schiffhorst G; Sterzel A; Grass U; Häussler B
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):854-8. PubMed ID: 17323403
[TBL] [Abstract][Full Text] [Related]
12. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
[TBL] [Abstract][Full Text] [Related]
13. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
[TBL] [Abstract][Full Text] [Related]
14. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients.
Lee YC; Chang CH; Lin JW; Chen HC; Lin MS; Lai MS
Liver Int; 2012 May; 32(5):859-66. PubMed ID: 22226322
[TBL] [Abstract][Full Text] [Related]
15. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.
Mamdani M; Rochon PA; Juurlink DN; Kopp A; Anderson GM; Naglie G; Austin PC; Laupacis A
BMJ; 2002 Sep; 325(7365):624. PubMed ID: 12242172
[TBL] [Abstract][Full Text] [Related]
16. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
[TBL] [Abstract][Full Text] [Related]
17. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study.
Schmidt M; Christiansen CF; Mehnert F; Rothman KJ; Sørensen HT
BMJ; 2011 Jul; 343():d3450. PubMed ID: 21727167
[TBL] [Abstract][Full Text] [Related]
18. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
[TBL] [Abstract][Full Text] [Related]
19. Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
McCarthy DM
Eur J Surg Suppl; 2002; (587):89-99. PubMed ID: 16144207
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
